Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors
Authors
GarraldaE1
FiedlerW2
MatosI3
RollingC4
KebenkoM4
KlinghammerK5
ConteG5
RaspagliesiF5
HabelB5
BaumeisterH5
OchsenreitherS5
ZurloA6
Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Barcelona, Spain
University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, GermanyMedical Oncology Department, Vall d’Hebron Hospital, Barcelona, SpainUniversity Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, Germany, Mologen AG, Berlin, GermanyUniversity Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, Germany, Mologen AG, Berlin, GermanyUniversity Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany, N/A, Germany, Mologen AG, Berlin, Germany